Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial

SAİP, Pınar; Eralp, Y.; AYDOĞMUŞ ŞEN, Fatma; Karaca, H.; ÖZKAN, METİN; ÇETİN, BEKİR; Benekli, M.; Kucukoner, M.; Isikdogan, A.; Un, O.; BAŞARAN, Gül; Onur, H.

doi:10.1016/j.breast.2013.07.048

Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial

Atıf İçin Kopyala

SAİP P. M., Eralp Y., AYDOĞMUŞ ŞEN F., Karaca H., ÖZKAN M., ÇETİN B. E., ...Daha Fazla

BREAST, cilt.22, sa.5, ss.628-633, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 5
Basım Tarihi: 2013
Doi Numarası: 10.1016/j.breast.2013.07.048
Dergi Adı: BREAST
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.628-633
Anahtar Kelimeler: HER2 positive, Lapatinib, Metastatic breast cancer, Vinorelbine, PLUS VINORELBINE, 1ST-LINE THERAPY, TRASTUZUMAB, SURVIVAL, GROWTH
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Background: The aim of this explorative phase II study was to evaluate the activity and safety of lapatinib in combination with intravenous vinorelbine in women with HER2 positive metastatic or recurrent breast cancer.